Yinhua CSI Innovative Drugs Industry ETF (159992) rose 2.39%, with its scale increasing by RMB 661 million over the past 1 week

NewTimeSpace News, as of 13:45 on August 13, 2026, Yinhua CSI Innovative Drugs Industry ETF (159992) rose 2.39%, with the latest price at RMB 0.94. Over a longer horizon, as of August 12, 2026, Yinhua CSI Innovative Drugs Industry ETF has gained a cumulative 6.12% over the past 1 week.

In terms of liquidity, Yinhua CSI Innovative Drugs Industry ETF recorded an intraday turnover rate of 6.71% with a turnover of RMB 1.244 billion. Over a longer horizon, as of August 12, the ETF's average daily turnover over the past 1 week was RMB 1.423 billion, ranking first among comparable funds.

In terms of size, Yinhua CSI Innovative Drugs Industry ETF's scale grew by RMB 661 million over the past 1 week, achieving significant growth, with the newly added AUM ranking 1st out of 7 among comparable funds. (Data source: Wind)

In terms of shares outstanding, Yinhua CSI Innovative Drugs Industry ETF's shares increased by 747 million over the past 3 months, achieving significant growth, with the newly added shares ranking 3rd out of 7 among comparable funds. (Data source: Wind)

Data shows that leveraged funds continue to build positions. Yinhua CSI Innovative Drugs Industry ETF's latest margin buying amount reached RMB 88.2622 million, and its latest margin balance reached RMB 631 million. (Data source: Wind)

As of August 12, Yinhua CSI Innovative Drugs Industry ETF's net value rose 8.87% over the past 6 months, ranking 769th out of 4,900 among index equity funds, placing it in the top 15.69%. In terms of return capability, as of August 12, 2026, since its inception, Yinhua CSI Innovative Drugs Industry ETF has achieved a highest monthly return of 22.79%, a longest streak of consecutive monthly gains of 4 months, a longest cumulative gain during a winning streak of 53.27%, and an average return in up months of 6.39%. As of August 12, 2026, Yinhua CSI Innovative Drugs Industry ETF's annualized excess return over the benchmark over the past 3 months was 5.51%.

In terms of drawdown, as of August 12, 2026, Yinhua CSI Innovative Drugs Industry ETF's drawdown relative to the benchmark over the past half year was 0.18%. The number of days to recovery after the drawdown was 28 days, the fastest recovery among comparable funds.

In terms of fees, Yinhua CSI Innovative Drugs Industry ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%.

In terms of tracking accuracy, as of August 12, 2026, Yinhua CSI Innovative Drugs Industry ETF's tracking error over the past 1 month was 0.033%, with relatively high tracking accuracy among comparable funds.

Yinhua CSI Innovative Drugs Industry ETF closely tracks the CSI Innovative Drugs Industry Index. The CSI Innovative Drugs Industry Index selects no more than 50 of the most representative listed company securities from those whose main business involves innovative drug R&D as index constituents, so as to reflect the overall performance of securities of innovative-drug-industry listed companies.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.